Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Mannanoligosaccharides (MOS) are prebiotic fibers derived primarily from the cell walls of yeast (Saccharomyces cerevisiae). Their use in supporting or treating colitis, especially inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease, is based on their potential to modulate gut microbiota and immune responses. Several animal studies have investigated the effects of MOS supplementation on colitis models, showing some beneficial effects such as reduced inflammation, improved intestinal barrier function, and favorable changes in gut microbial composition. For example, research in rodent models of chemically induced colitis has indicated that MOS can decrease pro-inflammatory cytokine production and enhance populations of beneficial bacteria like Lactobacillus and Bifidobacterium. However, robust human clinical data are lacking. Most evidence is preclinical, and results from animal studies do not always translate directly to human disease. Systematic reviews and meta-analyses on prebiotics for colitis generally note that while MOS and related oligosaccharides are promising, more high-quality human trials are needed. Currently, MOS is sometimes included in dietary supplements aimed at gut health, but it is not a standard or widely endorsed treatment for colitis. Overall, while there is a scientific rationale and preliminary evidence supporting MOS for colitis, the strength of evidence is currently limited, justifying a moderate-low rating.

More about Mannanoligosaccharides
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by Mannanoligosaccharides

Products containing Mannanoligosaccharides